TET1 Inhibition Promotes Therapeutic Sensitivity in TP53‐Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology
An association between reduced P53 function and increased expression of the epigenetic regulator TET1 in GBM models is identified, suggesting that TET1 may serve as a potential mediator of therapy resistance and a promising therapeutic target in TP53mut GBM.